Articles tagged "Kidney transplantation"

2019 American Transplant Congress
Social Determinants of Quality of Life in Patients Evaluated for Kidney Transplant
H. Wesselman¹, S. Wang², C. J. Chang², J. R. Pleis³, K. Kendall², E. Croswell², M. Dew², M. L. Unruh⁴, R. Shapiro⁵, L. Myaskovsky⁴
¹University of Notre Dame, Notre Dame, IN, ²University of Pittsburgh, Pittsburgh, PA, ³US Centers for Disease Control and Prevention, Hyattsville, MD, ⁴Department of Internal Medicine, University of New Mexico, School of Medicine, Albuquerque, NM, ⁵Icahn School of Medicine, New York, NY
*Purpose: Non-Hispanic African Americans (AA) have a higher incidence of ESRD but lower rates of kidney transplant (KT), and poorer quality of life (QOL) compared…
2019 American Transplant Congress
Identification of Rare Genetic Disorders in Kidney Transplantation Recipients with Un-Diagnosed Nephropathy through NGS Approach
G. Castellano, M. Giliberti, P. Pontrelli, M. Gigante, S. Diella, M. Accetturo, E. Stea, A. Mitrotti, L. Gesualdo
Emergency and Organ Transplantation, University of Bari, Bari, Italy
*Purpose: About 10% of end stage renal disease (ESRD) patients have no diagnosis of the primary kidney disease. Patients with unknown renal pathology can access…
2019 American Transplant Congress
In Depth Look at Acute Rejections in LCP-Tacrolimus (LCPT; Envarsus XR) and Immediate-Release Tacrolimus (IR-Tac)-Treated De Novo Kidney Transplant Recipients
A. Condon¹, M. Mujtaba², S. J. Patel³, D. R. Stevens³, U. Meier-Kriesche³
¹University of New Mexico Hospitals, Albuquerque, NM, ²University of Texas Medical Branch, Galveston, TX, ³Veloxis Pharmaceuticals Inc., Cary, NC
*Purpose: A prospective, randomized controlled trial has shown comparable rates of biopsy-proven rejection (BPAR) between LCPT and IR-Tac treated renal transplant recipients. This analysis aims…
2019 American Transplant Congress
Impact of Prolonged Venous Thromboembolism Prophylaxis on 30-Day Hemostatic Outcomes Following Kidney Transplantation in Patients with Hypercoagulable Risk Factors
V. Behbahani, A. Santeusanio, S. Ames, R. Shapiro
Mount Sinai Hospital, New York, NY
*Purpose: A number of hypercoagulable states have been identified through laboratory testing that place patients at greater risk for thrombosis; however, the appropriate management of…
2018 American Transplant Congress
Ischemia Reperfusion Injury & Risk for Antibody Mediated Rejection (ABMR) in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH)
A. Vo,¹ O. Aubert,² J. Choi,¹ N. Ammerman,¹ H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Ischemia reperfusion injury (IRI) contributes to delayed graft function (DGF). IRI/DGF in HLA-sensitized (HS) patients likely activates innate and memory injury pathways that may…
2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
S. Mulgaonkar,¹ Y. Qazi,¹ D. Kim,¹ V. Peddi,¹ K. McCague,² D. Patel,² A. Wiseman.¹
¹TRANSFORM Study Group, Livingston; ²Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
2018 American Transplant Congress
Molecular Profiling of the Injury-Repair Response in Early Subclinical Inflammation
M. Seifert, D. Della Manna, X. Liu, F. Rosenblum, M. Yanik, E. Yang, J. Pollock, R. Mannon.
UAB School of Medicine, Birmingham.
Purpose: Surveillance biopsies can detect subclinical T-cell mediated rejection (SC-TCMR) or subclinical borderline rejection (SC-B-TCMR) in kidney transplants with normal/stable creatinine. Some consider SC-B-TCMR to…
2018 American Transplant Congress
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry
S. Sanoff,¹ K. Ravindra,¹ W. Irish.^1,2
¹Duke University Medical Center, Durham, NC; ²CTI Consulting, Raleigh, NC.
Introduction:Belatacept (BEL) was FDA approved for Kidney Transplantation (KTx) June 2011. It has largely been evaluated in two controlled trials (N Engl J Med 2016;374:333-43).…
2018 American Transplant Congress
Evolving Etiologies for Readmissions and Their Impact on Graft Survival in Kidney Transplantation
D. Taber, N. Pilch, Z. Su, C. Mardis, J. Fleming, N. Patel, H. Meadows, P. Mauldin, V. Rao, D. Dubay.
MUSC, Charleston, SC.
Background: Although readmissions after kidney transplant are a well-known risk factor for graft loss, it is unclear if certain etiologies are associated with poorer outcomes…
2018 American Transplant Congress
Kidney Transplant Allocation with CMV Seromatching Reduces CMV Infection without Affecting Wait Times
A. Narra,¹ L. Strasfeld,² D. Basuli,¹ M. Stack,¹ E. Langewisch,³ A. Olyaei,¹ D. Norman,^1,4 J. Lockridge.^1,4
¹Transplant Nephrology, Oregon Health and Science University, Portland, OR; ²Infectious Diseases, OHSU, Portland, OR; ³Transplant Nephrology, University of Nebraska Medical Center, Omaha, NE; ⁴Transplant Nephrology, Portland VA, Portland, OR.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in kidney transplant recipients.A pre-transplant allocation strategy by matching deceased kidney donors and recipients…